Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of HPV9v in HIV+ MSM
NCT03626467Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Fundación SEIMC-GeSIDA. Started Oct 2018; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03626467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626467.